Nimish Vakil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nimish Vakil has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Aboud Affi
Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin Medical School, Milwaukee, Wisconsin
1 shared publicationB Hahn
1 shared publicationB. Hamelin
AstraZeneca LP, Wayne, PA, USA
1 shared publicationC. Hwang
AstraZeneca LP, Wayne, PA, USA
1 shared publicationChristino Canga
University of Wisconsin Medical School, Aurora Sinai Medical Center, 945 North 12th Street, Room 4040, Milwaukee, WI 53233, USA
1 shared publicationD. A. Johnson
Eastern Virginia School of Medicine, Norfolk, VA, USA
1 shared publication
Latest Publications
- 3 March 2009
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 104 (S2) , S17-S20
Acid Inhibition and Infections Outside the Gastrointestinal Tract
The American Journal of Gastroenterology is published by Nature Publishing Group (NPG) on behalf of the American College of Gastroenterology (ACG). Ranked the #1 clinical journal covering gastroenterology and hepatology*, The American Journal of Gastroenterology (AJG) provides practical and professional support for clinicians dealing with the gastroenterological disorders seen most often in patients. Published with practicing clinicians in mind, the journal aims to be easily accessible, organizing its content by topic, both online and in print. www.amjgastro.com, *2007 Journal Citation Report (Thomson Reuters, 2008)
- 3 March 2009
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 104 (S2) , S17-S20
Acid Inhibition and Infections Outside the Gastrointestinal Tract
The American Journal of Gastroenterology is published by Nature Publishing Group (NPG) on behalf of the American College of Gastroenterology (ACG). Ranked the #1 clinical journal covering gastroenterology and hepatology*, The American Journal of Gastroenterology (AJG) provides practical and professional support for clinicians dealing with the gastroenterological disorders seen most often in patients. Published with practicing clinicians in mind, the journal aims to be easily accessible, organizing its content by topic, both online and in print. www.amjgastro.com, *2007 Journal Citation Report (Thomson Reuters, 2008)
- 1 March 2009
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 104, S17-S20
Acid Inhibition and Infections Outside the Gastrointestinal Tract
Anisms can occur in patients taking acid suppressive agents. In mechanically ventilated patients, colonization of the oropharynx and stomach may predispose to Gram-negative pneumonias. Despite the associations between acid inhibitor use and pneumonia shown in some studies, the data on community-acquired pneumonias are not conclusive. In clinical practice, prudence would dictate that the need for acid inhibition with histamine-2 receptor antagonists or proton pump inhibitors should be carefully considered in patients who are at risk for pneumonias (elderly patients with chronic lung disease who are on immunosuppressive drugs or corticosteroids and patients with recurrent lung infections requiring frequent antibiotic therapy)....
- 1 March 2009
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 104, S17-S20
Acid Inhibition and Infections Outside the Gastrointestinal Tract
Anisms can occur in patients taking acid suppressive agents. In mechanically ventilated patients, colonization of the oropharynx and stomach may predispose to Gram-negative pneumonias. Despite the associations between acid inhibitor use and pneumonia shown in some studies, the data on community-acquired pneumonias are not conclusive. In clinical practice, prudence would dictate that the need for acid inhibition with histamine-2 receptor antagonists or proton pump inhibitors should be carefully considered in patients who are at risk for pneumonias (elderly patients with chronic lung disease who are on immunosuppressive drugs or corticosteroids and patients with recurrent lung infections requiring frequent antibiotic therapy)....
- 1 May 2008
- Published by S. Karger AG in Digestive Diseases
- Vol. 26 (3) , 215-217
Proton Pump Inhibitors for Dyspepsia
Proton pump inhibitors are widely used in many upper gastrointestinal disorders. Dyspepsia is a common problem in primary care and endoscopy is neither feasible nor affordable in the majority of patients. Helicobacter pylori eradication has been shown to be effective, but with the declining prevalence of H. pylori infection in Western countries, alternate strategies are necessary. Proton pump inhibitor therapy is one such alternative and has already been adopted in dyspepsia management guidelines in the USA, UK and Canada. Cost-effectiveness studies suggest that in young patients acid suppression alone is more cost-effective than either endoscopy or testing and treatment for H. pylori in areas with a low prevalence of H. pylori.
- 1 May 2008
- Published by S. Karger AG in Digestive Diseases
- Vol. 26 (3) , 215-217
Proton Pump Inhibitors for Dyspepsia
Proton pump inhibitors are widely used in many upper gastrointestinal disorders. Dyspepsia is a common problem in primary care and endoscopy is neither feasible nor affordable in the majority of patients. Helicobacter pylori eradication has been shown to be effective, but with the declining prevalence of H. pylori infection in Western countries, alternate strategies are necessary. Proton pump inhibitor therapy is one such alternative and has already been adopted in dyspepsia management guidelines in the USA, UK and Canada. Cost-effectiveness studies suggest that in young patients acid suppression alone is more cost-effective than either endoscopy or testing and treatment for H. pylori in areas with a low prevalence of H. pylori.
- 1 January 2008
- Published by S. Karger AG in Digestive Diseases
- Vol. 26 (3) , 193
Introduction
- 1 September 2004
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 16 (9) , 853-856
Long-term strategies
Gastro-oesophageal reflux disease is a chronic medical condition that is associated with substantial morbidity and impairment of quality of life. The long-term management of the disease requires consideration of treatment efficacy and cost and must meet the needs of patients, physicians and third-party payers.
- 1 September 2004
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 16 (9) , 853-856
Long-term strategies
Gastro-oesophageal reflux disease is a chronic medical condition that is associated with substantial morbidity and impairment of quality of life. The long-term management of the disease requires consideration of treatment efficacy and cost and must meet the needs of patients, physicians and third-party payers.
- 3 June 2003
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 35 (6) , 526-530
Pneumatic Dilation in Achalasia
Achalasia is a primary disorder of esophageal motor function, of unknown etiology, that is characterized by insufficient or absent lower esophageal sphincter (LES) relaxation and loss of peristalsis in the esophagus. These abnormalities are recognized radiographically by aperistalsis, esophageal dilation, and decreased opening of the LES, with a characteristic “bird-beak” appearance. The principal symptom of this disorder is dysphagia and pneumatic dilation is designed to alleviate or cure this symptom.
- 3 June 2003
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 35 (6) , 526-530
Pneumatic Dilation in Achalasia
Achalasia is a primary disorder of esophageal motor function, of unknown etiology, that is characterized by insufficient or absent lower esophageal sphincter (LES) relaxation and loss of peristalsis in the esophagus. These abnormalities are recognized radiographically by aperistalsis, esophageal dilation, and decreased opening of the LES, with a characteristic “bird-beak” appearance. The principal symptom of this disorder is dysphagia and pneumatic dilation is designed to alleviate or cure this symptom.
- Open Access
- 1 February 2003
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 17 (s1) , 21-23
Review article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis
Background : Proton pump inhibitors are the most effective agents for treating erosive oesophagitis, but their relative efficacies have not been well characterized in large clinical trials. Aim : To compare standard doses of esomeprazole and lansoprazole in healing oesophagitis and resolving accompanying symptoms. Methods : This was a US, multicentre, randomized, double‐blind trial and included 5241 adult patients (intention‐to‐treat) with endoscopically documented erosive oesophagitis. Patients were randomized to esomeprazole, 40 mg once daily, or lansoprazole, 30 mg once daily, for up to 8 weeks. The primary end‐point, endoscopic healing at Week 8, was assessed using life‐table analysis and a log‐rank test. Secondary endpoints included healing at Week 4, healing according to baseline severity of oesophagitis, control of heartburn and side‐effects. Results : Healing rates were 92.6% with esomeprazole and 88.8% with lansoprazole at Week 8 (P = 0.0001, log‐rank test). A significant difference was also observed at Week 4. Sustained resolution of heartburn occurred faster and in a larger proportion of patients treated with esomeprazole. Both agents were well tolerated. Conclusions : Esomeprazole produced significantly higher oesophagitis healing rates than lansoprazole over all grades of oesophagitis. Esomeprazole also provided better control of heartburn and was associated with a greater proportion of patients with sustained resolution of symptoms.
- 1 February 2003
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 17 (s1) , 21-23
Open AccessReview article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis
Background : Proton pump inhibitors are the most effective agents for treating erosive oesophagitis, but their relative efficacies have not been well characterized in large clinical trials. Aim : To compare standard doses of esomeprazole and lansoprazole in healing oesophagitis and resolving accompanying symptoms. Methods : This was a US, multicentre, randomized, double‐blind trial and included 5241 adult patients (intention‐to‐treat) with endoscopically documented erosive oesophagitis. Patients were randomized to esomeprazole, 40 mg once daily, or lansoprazole, 30 mg once daily, for up to 8 weeks. The primary end‐point, endoscopic healing at Week 8, was assessed using life‐table analysis and a log‐rank test. Secondary endpoints included healing at Week 4, healing according to baseline severity of oesophagitis, control of heartburn and side‐effects. Results : Healing rates were 92.6% with esomeprazole and 88.8% with lansoprazole at Week 8 (P = 0.0001, log‐rank test). A significant difference was also observed at Week 4. Sustained resolution of heartburn occurred faster and in a larger proportion of patients treated with esomeprazole. Both agents were well tolerated. Conclusions : Esomeprazole produced significantly higher oesophagitis healing rates than lansoprazole over all grades of oesophagitis. Esomeprazole also provided better control of heartburn and was associated with a greater proportion of patients with sustained resolution of symptoms.
- 1 January 2003
- Published by Elsevier in The American Journal of Medicine
- Vol. 114 (1) , 1-5
Clinical effectiveness of laparoscopic fundoplication in a U.S. community
- 1 January 2003
- Published by Elsevier in The American Journal of Medicine
- Vol. 114 (1) , 1-5
Clinical effectiveness of laparoscopic fundoplication in a U.S. community
- 1 January 2003
- Published by Elsevier in Gastrointestinal Endoscopy Clinics of North America
- Vol. 13 (1) , 69-73
An overview of the success and failure of surgical therapy: standards against which the outcome of endoscopic therapy is measured.
- 1 January 2003
- Published by Elsevier in Gastrointestinal Endoscopy Clinics of North America
- Vol. 13 (1) , 69-73
An overview of the success and failure of surgical therapy: standards against which the outcome of endoscopic therapy is measured.
- 1 December 2002
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 31 (4) , S85-S88
Novel methods of using proton-pump inhibitors.
- 1 December 2002
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 31 (4) , S85-S88
Novel methods of using proton-pump inhibitors.